Pharma Industry

BNET Pharma Insights

Pharma Articles

• Sanofi Hit By Generic Plavix Threat in Europe

  By Ben Hirschler LONDON (Reuters) - French drugmaker Sanofi-Aventis (SASY), which briefly encountered generic competition to its second-biggest product Plavix in the United States in 2006 and 2007, now faces a similar threat in Europe. Schweizerhall (SWHN), a Swiss generic drug company, said...

  Fri May 9, 2008 @ 12:00 PM PDT

  Tags: Financial accounting, drug company, Sanofi-Aventis, Luxembourg, Germany, Europe, London, patent, Thomson Reuters Corp., license agreement, intellectual property right, marketing, stock, analyst, earnings per share, U.S., intellectual property, sales, security

• Takeda Sees Big Profit Slump on Millennium Costs

  By Edwina Gibbs TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 77 percent drop in quarterly operating profit as it spent to boost its pipeline, and forecast a sharp fall in annual income linked to the costs of its $8...

  Fri May 9, 2008 @ 5:00 AM PDT

  Tags: Millennium Pharmaceuticals Inc., VELCADE, Amgen Inc., biotechnology, Tokyo, pharmaceutical company, Merrill Lynch & Co. Inc., earnings, analyst, stock, acquisition, Thomson Reuters Corp., U.S., sales, agreement, benefit

• Takeda Sees Big Profit Slump on Millennium Costs

  TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 7.7 percent fall in annual operating profit on Friday and forecast a sharp drop for the current year on costs for its $8.8 billion purchase of U.S. biotech firm Millennium...

  Thu May 8, 2008 @ 10:30 PM PDT

  Tags: Sales strategy, Tokyo, pharmaceutical company, Japan, Thomson Reuters Corp., sales, Medicare, acquisition, licensing agreement, R&D, analyst, U.S., tax

• Drugmakers Need to Rein in Ads, Hearing Told

  By Susan Heavey WASHINGTON (Reuters) - Pharmaceutical companies need to be more responsible in touting products to consumers or else face tighter controls from Congress, a top U.S. Democratic lawmaker said on Thursday. Rep. Bart Stupak, at a hearing to discuss specific ads...

  Thu May 8, 2008 @ 1:30 PM PDT

  Tags: Schering-Plough Corp., Merck & Co. Inc., Pfizer Inc., pharmaceutical company, drug company, physician, patient, advertisement, U.S. Congress, Washington, risk, TV, benefit, Thomson Reuters Corp., food, technique, knowledge, marketing, sales

• Schering-Plough Now in the Feds' Crosshairs

  The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries.  Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...

  Wed May 7, 2008 @ 4:44 PM PDT

  Tags: SEC, Merck & Co. Inc., Schering-Plough Corp., Attorney, Vytorin, Sales Strategy, Healthcare, Sales Force Management, Sales, David P. Hamilton

• Glaxo Bond Boosts Chances of Euro Mega Deals

  By Natalie Harrison LONDON (Reuters UK) - GlaxoSmithKline's (GSK) well-received $9 billion (4.6 billion pound) bond this week, the largest dollar issue by a non-U.S. corporate in seven years, has raised confidence of possible euro mega deals in the next few months. The success of the...

  Wed May 7, 2008 @ 8:45 AM PDT

  Tags: Bond, Investor, Citigroup Inc., Investment, Financial Accounting, Finance, GlaxoSmithKline Plc., Oukbs

• Medtronic to Cut About 1,100 Jobs

  By Susan Kelly CHICAGO (Reuters) - Medtronic Inc (MDT) on Tuesday said it would eliminate about 1,100 jobs this year, or almost 3 percent of its work force, in businesses whose growth has slowed, including its flagship heart rhythm device unit. The company...

  Tue May 6, 2008 @ 1:01 PM PDT

  Tags: Mergers & Acquisitions, Financial accounting, HEALTHCARE, Medtronic Inc., medical device, earnings, Chicago, Thomson Reuters Corp., acquisition

• Emergent's Vaccine Play: Biotech Can Flip-Flop, Too

  For sudden twists of fate, abrupt collapses and the occasional stunning revival, it's hard to beat the biotech industry. Yesterday, for instance, the all-but-dead biotech VaxGen agreed to sell off its ailing anthrax vaccine to its East Coast rival Emergent BioSolutions --a company that spent much of this decade trying...

  Tue May 6, 2008 @ 6:19 AM PDT

  Tags: Biotechnology, Vaccine, Emergent Biosolutions, VaxGen, Healthcare, David P. Hamilton

• Pfizer Drops Glaucoma Drug, NicOx Shares Slump

  PARIS (Reuters) - Pfizer (PFE) has decided not to take NicOx's (NCOX) experimental glaucoma drug PF-03187207 into final Phase III tests after a mid-stage study failed to met its primary endpoint, sending NicOx shares tumbling. The news is a major blow for NicOx,...

  Tue May 6, 2008 @ 12:45 AM PDT

  Tags: Pfizer Inc., endpoint, compound, Paris, biotechnology, Thomson Reuters Corp., patient, collaboration

• Man Bites Dog: Former Merck CEO Blasts High Drug Prices

  Most pharmaceutical companies insist that high drug prices are a natural consequence of the risky business of drug discovery, and that huge profits on marketed drugs are necessary to cover the costs of the 5,000 to 10,000 experimental drugs that fail for every one that succeeds. In fact, there are...

  Mon May 5, 2008 @ 1:59 AM PDT

  Tags: Industry, Dr., Merck & Co. Inc., Pharmaceutical Company, Drug, Pricing, Strategy, Marketing, Management, David P. Hamilton

• European Stocks Pause After Rally

  By Blaise Robinson PARIS (Reuters UK) - European stocks dipped in early trade on Monday, as comments by U.S. influential investor Warren Buffett that said the U.S. economy was in recession prompted investors to take a breather after last week's lofty gains. Trading volumes remained low...

  Mon May 5, 2008 @ 1:30 AM PDT

  Tags: Yahoo! Inc., Equity, Warren Buffett, Investment, Access Pharmaceuticals Inc., Microsoft Corp., Sprint Nextel Corp., US

• Government Seen Risking Business Exodus Over Tax

  LONDON (Reuters UK) - Some of the biggest names in British business have told the government that it risks a corporate exodus if it presses ahead with tax proposals on foreign earnings, newspapers said on Sunday. The Sunday Times and Sunday Telegraph said a delegation ...

  Sun May 4, 2008 @ 8:15 AM PDT

  Tags: Government, Exodus Communications, Taxes, Free Trade, Financial Planning, GlaxoSmithKline Plc., Tax, Vodafone Group Plc.

• P&G Sues J&J Over Tooth-whitening Strip Patent

  LOS ANGELES (Reuters) - Procter & Gamble Co (PG) said on Friday it sued Johnson & Johnson (JNJ), claiming that J&J's Listerine Whitening Quick Dissolving Strips violate P&G patents. The lawsuit, filed on Friday in the U.S. District Court for the...

  Fri May 2, 2008 @ 3:30 PM PDT

  Tags: Johnson & Johnson, Procter & Gamble Co., patent, Los Angeles, pending litigation, Thomson Reuters Corp.

• Pfizer Reaches Deal With Some Celebrex Users: Report

  NEW YORK (Reuters) - Pfizer Inc (PFE) has reached tentative deals with some patients who claim to have suffered heart attacks and strokes from taking the company's Celebrex and Bextra pain medicines, the Wall Street Journal said on Friday, citing plaintiff...

  Fri May 2, 2008 @ 1:45 PM PDT

  Tags: Pfizer Inc., law firm, attorney, patient, pending litigation, lawyer, New York, advisor, Thomson Reuters Corp., litigation, benefit

• Pfizer Invests $300 Mln in Irish Biotech Facility

  LONDON (Reuters) - Pfizer Inc (PFE), the world's biggest drugmaker, is to invest 190 million euros ($297 million) establishing a new biotech plant in Ireland for the production of experimental medicines, it said on Friday. The facility, which will create around 100 permanent...

  Fri May 2, 2008 @ 2:45 AM PDT

  Tags: Pfizer Inc., drug company, biotechnology, Ireland, clinical trial, London, Thomson Reuters Corp., leader, manufacturing, job

• Merck Extends Deadline For Vioxx Settlement

  NEW YORK (Reuters) - Merck & Co (MRK) said on Thursday at least 94 percent of eligible U.S. claimants have elected to participate in its $4.85 billion proposed Vioxx settlement, and the drugmaker extended the deadline for the remainder to join ...

  Thu May 1, 2008 @ 4:00 PM PDT

  Tags: Litigation, Merck & Co. Inc., settlement, proposed settlement, drug company, stroke, patient, lawsuit, U.S., New York, Thomson Reuters Corp.

• Esperion Escapes the Pfizer Borg

  Esperion Therapeutics, a biotech that Pfizer spent $1.3 billion acquiring in 2003, is free once more. And its founder, Roger Newton, is apparently putting the band back together. Newton, in fact, has just pulled off one of the rarer and most complicated moves in biotechnology -- the...

  Thu May 1, 2008 @ 3:50 PM PDT

  Tags: Pfizer Inc., Esperion, Biotechnology, Mergers & Acquisitions, Investment, Finance, David P. Hamilton

• Drugmakers Win Appeal Over Alzheimer Curbs

  By Ben Hirschler LONDON (Reuters UK) - An appeals court on Thursday ruled the country's healthcare cost-effectiveness watchdog had acted unfairly in the way it decided to curb access to Alzheimer's drugs, in a victory for drugmakers and patients. The move will let manufacturers renew their...

  Thu May 1, 2008 @ 5:47 AM PDT

  Tags: Alzheimer's Disease, Patient, Health Care, NICE, QALY, Johnson & Johnson, Noven Pharmaceuticals Inc., Pfizer Inc.

• Glaxo Wins U.S. FDA Approval For Wider Advair Use

  By Susan Heavey WASHINGTON (Reuters UK) - U.S. health regulators have said GlaxoSmithKline Plc's (GSK)(GSK) Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease (COPD), the drugmaker said on Wednesday. Glaxo's approval comes the same day as rival AstraZeneca...

  Wed Apr 30, 2008 @ 4:00 PM PDT

  Tags: AstraZeneca Plc., FDA, Patient, Glaxo, Advair, Federal Government, Government, GlaxoSmithKline Plc.

• Glaxo Wins FDA Approval For Wider Advair Use

  WASHINGTON (Reuters) - U.S. health regulators have said GlaxoSmithKline Plc's (GSK)(GSK) Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease (COPD), the drugmaker said on Wednesday. Glaxo's approval comes the same day as rival AstraZeneca...

  Wed Apr 30, 2008 @ 3:00 PM PDT

  Tags: HEALTHCARE, GlaxoSmithKline Plc., patient, clinical trial, Pfizer Inc., London, Thomson Reuters Corp., health care, sales

• More recent Pharma Articles »
• « Earlier Pharma Articles